The American biotechnology company Novavax announced on Thursday (24) that it has started a final phase clinical trial in the United Kingdom for its experimental vaccine against covid-19, the 11th vaccine in the world to reach this level of development.
The test aims to include 10,000 participants aged between 18 and 84 years. “Due to the current high level of transmission of SARS-CoV-2, and given that it is likely to remain high in the UK, we are optimistic that the study will recruit quickly and produce results in the short term,” said Gregory Glenn, director of pharmaceutical research and development, in a note.
It is the eleventh vaccine candidate in the world to enter phase 3 clinical trials, the last one, involving tens of thousands of people. Half of them receive a placebo and the other half receive the vaccine.
The most advanced western projects are those developed by the British company AstraZeneca, in partnership with the University of Oxford, and by the American companies Pfizer and Moderna. The Chinese and Russian projects have also reached the final stage.
Novavax is one of six companies funded by the United States government to develop the vaccine. It received more than $ 1.6 billion in public resources to finance the production of 100 million doses.